Atul Pratap Singh, Wasim Akhtar, Saif Alam, Naziya
{"title":"Recent Advances and Clinical Approach to Cancer Treatment with Nanotechnology Derived Biomolecule.","authors":"Atul Pratap Singh, Wasim Akhtar, Saif Alam, Naziya","doi":"10.2174/0122117385297455240508055620","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer nanomedicine has the potential to take advantage of the multifunctionality and diverse biological activity of nanostructures based on biomolecules. Novel drug delivery vehicles can be designed by programming the supramolecular features of biomolecules to achieve multiple therapeutic goals at once, including efficient in vivo transport and targeted drug administration. Proteins, peptides, nucleic acids, and polysaccharides can all be engineered into multipurpose nanomedicines. Even while numerous cancer medications reduce mortality, they are still insufficient. Early cancer cell detection and high-specificity therapeutic administration optimise treatment and prevent toxicity. Nanotechnology is improving cancer diagnosis and treatment due to increased systemic toxicity and refractoriness with current methods. Nanotechnology-based immunotherapeutic drugs have reduced cancer cell invasiveness while protecting healthy cells in several cancer types. Carbon nanotubes, polymeric micelles, and liposomes improve cancer medication pharmacokinetics and pharmacodynamics. Nanomedicines' use in patient care and promising nanotechnology-based cancer interventions have been covered in this article. Nanomaterials used in treating cancer have been discussed. Additionally, nanomaterial obstacles that hinder their applicability and clinical translation in certain cancer types are addressed.</p>","PeriodicalId":19774,"journal":{"name":"Pharmaceutical nanotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122117385297455240508055620","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer nanomedicine has the potential to take advantage of the multifunctionality and diverse biological activity of nanostructures based on biomolecules. Novel drug delivery vehicles can be designed by programming the supramolecular features of biomolecules to achieve multiple therapeutic goals at once, including efficient in vivo transport and targeted drug administration. Proteins, peptides, nucleic acids, and polysaccharides can all be engineered into multipurpose nanomedicines. Even while numerous cancer medications reduce mortality, they are still insufficient. Early cancer cell detection and high-specificity therapeutic administration optimise treatment and prevent toxicity. Nanotechnology is improving cancer diagnosis and treatment due to increased systemic toxicity and refractoriness with current methods. Nanotechnology-based immunotherapeutic drugs have reduced cancer cell invasiveness while protecting healthy cells in several cancer types. Carbon nanotubes, polymeric micelles, and liposomes improve cancer medication pharmacokinetics and pharmacodynamics. Nanomedicines' use in patient care and promising nanotechnology-based cancer interventions have been covered in this article. Nanomaterials used in treating cancer have been discussed. Additionally, nanomaterial obstacles that hinder their applicability and clinical translation in certain cancer types are addressed.
期刊介绍:
Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.